Macquarie Group’s Relmada Therapeutics RLMD Stock Holding History

Macquarie Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-856	Closed	-$4	–	2092
2024 Q1	$4	Buy	+856	New	+$4.13K	﹤0.01%	1818
2022 Q3	–	Sell	-116	Closed	-$3.21K	–	2466
2022 Q2	$2K	Hold	116	–	–	﹤0.01%	2559
2022 Q1	$3	Hold	116	–	–	﹤0.01%	2607
2021 Q4	$3K	Hold	116	–	–	﹤0.01%	2585
2021 Q3	$3K	Hold	116	–	–	﹤0.01%	2613
2021 Q2	$4K	Hold	116	–	–	﹤0.01%	2536
2021 Q1	$4K	Sell	116 -55	-32%	-$1.92K	﹤0.01%	2452
2020 Q4	$5K	Hold	171	–	–	﹤0.01%	2342
2020 Q3	$6K	Hold	171	–	–	﹤0.01%	2328
2020 Q2	$8K	Sell	171 -2,705	-94%	-$114K	﹤0.01%	2314
2020 Q1	$98K	Buy	+2,876	New	+$116K	﹤0.01%	1643

Other funds holding RLMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group's RLMD Position: Q2 2024 in Review

Macquarie Group sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 856 shares — an estimated $4 sold.

Macquarie Group first reported a position in RLMD in Q1 2020 and held it in 11 quarters. The position peaked at $98K in Q1 2020. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

Macquarie Group reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 856 Relmada Therapeutics shares in Q2 2024, an estimated $4.
Macquarie Group first reported a position in Relmada Therapeutics in Q1 2020 and held it in 11 quarters.
Macquarie Group's Relmada Therapeutics position peaked at $98K in Q1 2020.
79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.